Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
- 23 May 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (7), 946-957
- https://doi.org/10.1016/s1470-2045(17)30355-8
Abstract
No abstract availableFunding Information
- National Institutes of Health and NCI grants (U10 CA180899 and U10CA98413)
This publication has 59 references indexed in Scilit:
- Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaEuropean Journal of Cancer, 2012
- Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology GroupClinical Cancer Research, 2011
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid TumorsJournal of Clinical Oncology, 2011
- Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group StudyJournal of Clinical Oncology, 2011
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II StudyJournal of Clinical Oncology, 2010
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaThe New England Journal of Medicine, 2010
- Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group StudyJournal of Clinical Oncology, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958